Back to results
US 11,078,481 B1Granted
Methods for screening for cancer targets
AssigneeKSQ Therapeutics, Inc.
InventorMicah Benson
Life of this patent
Estimating the term…
Abstract
This invention describes a novel CRISPR/Cas9 target identification platform permitting the discovery of novel genes and pathways involved in the ability of T cells and NK cells to react against and generate an anti-tumor response.
Claims16
A method for obtaining T cells that are resistant to tumor suppression or deactivation, said method comprising:
- (a) obtaining a population of tumor cells that are engineered to express an extracellular protein target;
- (b) obtaining a primary cell population of T cells that are engineered to express:
- (i) a chimeric antigen receptor (CAR), said CAR comprising an intracellular signaling domain and an extracellular target-binding domain that binds to the extracellular protein target expressed by the population of tumor cells of (a), to form a population of CAR-T cells that express the extracellular target-binding domain on the cell surface, and
- (ii) a Cas9 protein and a gRNA library that selectively edit the CAR-T cells at one or more locations of the CAR-T cell genome to form a subpopulation of edited CAR-T cells;
- (c) co-culturing the subpopulation of edited CAR-T cells of (b) with the population of tumor cells of (a);
- and
- (d) isolating the edited CAR-T cells that accumulate over the co-culture period, wherein the isolated CAR-T cells have been edited in a manner as to make the CAR-T cells resistant to tumor suppression or deactivation, thereby obtaining T cells that are resistant to tumor suppression or deactivation.
4 more elements
A method for obtaining NK cells or NKT cells that are resistant to tumor suppression or deactivation, said method comprising:
- (a) obtaining a population of tumor cells that are engineered to express an extracellular protein target;
- (b) obtaining a primary cell population of NK cells or NKT cells that are engineered to express:
- (i) a chimeric antigen receptor (CAR), said CAR comprising an intracellular signaling domain and an extracellular target-binding domain that binds to the extracellular protein target expressed by the population of tumor cells of (a), to form a population of CAR-NK cells or CAR-NKT cells that express the extracellular target-binding domain on the cell surface, and
- (ii) a Cas9 protein and a gRNA library that selectively edit the CAR-NK cells or CAR-NKT cells in one or more locations of the CAR-NK cell genome or CAR-NKT cell genome to form a subpopulation of edited CAR-NK cells or edited CAR-NKT cells;
- (c) co-culturing the subpopulation of edited CAR-NK cells or edited CAR-NKT cells of (b) with the population of tumor cells of (a);
- (d) isolating the edited CAR-NK cells or edited CAR-NKT cells that accumulate over the co-culture period;
- wherein the isolated CAR-NK cells or CAR-NKT cells have been edited in a manner as to make said cells resistant to suppression or deactivation by said tumor, thereby obtaining NK cells or NKT cells that are resistant to tumor suppression or deactivation.
4 more elements
Dependencies are inferred from the claim text.